Long‐term clinical outcomes and healthcare utilization of sickle cell disease patients with <scp>COVID</scp>‐19: A 2.5‐year follow‐up study

Feit, Avery; Gordon, Moshe; Alamuri, Tharun T.; Hou, Wei; Mitchell, William B.; Manwani, Deepa; Duong, Timothy Q.

doi:10.1111/ejh.14058

Cited by 3 publications

(1 citation statement)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, patients with a documented history of atypical Parkinsonian disorders were excluded from the study (40 patients). Studies using an earlier version of this large database to address different questions have been reported [10][11][12][13][28][29][30][31][32][33][34][35][36][37].…”

Section: Data Sourcesmentioning

confidence: 99%

Long-term outcomes of patients with Parkinson’s disease 3.5 years post SARS-CoV-2 infection in an inner-city population in the Bronx

Hadidchi,

Al-Ani,

Piskun

et al. 2024

Preprint

View full text Add to dashboard Cite

Objectives. Although patients with pre-existing Parkinson’s disease (PD) are at a higher risk of severe acute COVID-19 outcomes compared to matched controls, the long-term outcomes of PD patients post SARS-CoV2 infection are largely unknown. This study investigated the clinical outcomes of patients with pre-existing PD up to 3.5 years post-infection in an inner-city population in the Bronx, New York. Methods. This retrospective study evaluated 3,512 patients with PD in the Montefiore Health System in the Bronx (January 2016 to July 2023), which serves a large Black and Hispanic population and was an epicenter of the early COVID-19 pandemic and subsequent surges of infections. COVID-19 status was defined by a positive polymerase-chain-reaction test. Comparisons were made with patients without a positive COVID-19 test. Outcomes were post-index date all-cause mortality, major adverse cardiovascular events (MACE), altered mental status, fatigue, dyspnea, headache, psychosis, dementia, depression, anxiety, dysphagia, falls, and orthostatic hypotension. Changes in Levodopa, a PD medication, prescriptions were also tabulated. Adjusted hazard ratios (aHR) were computed accounting for competing risks. Results. About 14% of PD patients had a positive COVID-19 test. PD patients with COVID-19 had similar demographics but a higher prevalence of pre-existing comorbidities and neurological disorders compared to PD patients without COVID-19. PD patients with COVID-19 had greater risk of mortality (aHR = 1.58 [95% CI:1.03,2.41] P = 0.03), MACE (HR = 1.57[95% CI:1.19,2.07], P < 0.005), dyspnea (aHR = 1.44 [1.11,1.87], P < 0.01), fatigue (aHR = 1.49 [1.12,1.97] P < 0.01), headache (HR = 1.35 [1.01,1.80] P = 0.04), and fall (aHR = 1.39 [1.01, 1.92] P = 0.04) compared to PD patients without COVID-19 up to 3.5 years post index-date. Levodopa equivalent dose adjustment was higher post-infection in the COVID-19 cohort compared to non-COVID-19 cohort (P < 0.04). Conclusions. PD patients with COVID-19 were at a higher risk of worse long-term outcomes compared to PD patients without COVID-19. Patients with PD who survive COVID-19 may benefit from heightened clinical awareness and close follow-up.

show abstract

Section: Data Sourcesmentioning

confidence: 99%

Long-term outcomes of patients with Parkinson’s disease 3.5 years post SARS-CoV-2 infection in an inner-city population in the Bronx

Hadidchi,

Al-Ani,

Piskun

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

SARS-CoV-2 infection increases long-term multiple sclerosis disease activity and all-cause mortality in an underserved inner-city population

Hadidchi,

Wang,

Rezko

et al. 2024

Multiple Sclerosis and Related Disorders

View full text Add to dashboard Cite

Long-Term outcomes of patients with a pre-existing neurological condition after SARS-CoV-2 infection

Hadidchi,

Al-Ani,

Choi

et al. 2024

Preprint

View full text Add to dashboard Cite

Objectives. This study investigated post COVID-19 outcomes of patients with pre-existing neurological conditions up to 3.5 years post-infection. Methods. This retrospective study consisted of 1,664 patients with COVID-19 (of which 1,320 had been hospitalized for acute COVID-19) and 8,985 non-COVID patients from the Montefiore Health System in the Bronx (Jan-2016 to Jul-2023). Primary outcomes were all-cause mortality and major adverse cardiovascular events (MACE) post-COVID-19. Secondary outcomes were depression, anxiety, fatigue, headache, sleep disturbances, altered mental status, and dyspnea post-COVID-19. Cox proportional hazards model was used to calculate adjusted hazard ratios for all-cause mortality and major adverse cardiovascular event (MACE). Cumulative incidence function and Fine-Gray sub-distribution hazards model analysis were performed for secondary outcomes. Results. Patients with a neurological disease hospitalized for COVID-19 were more likely to die (adjusted HR = 1.92 [CI:1.60, 2.30], P < 0.005), whereas patients non-hospitalized for COVID-19 had mortality rate (aHR = 1.08 [CI:0.65, 1.81], P = 0.76), compared to non-COVID patients. Patients with a neurological disease (hospitalized for COVID-19 aHR = 1.76 [CI:1.53, 2.03], P < 0.005; not hospitalized for COVID-19: aHR = 1.50 [CI:1.09, 2.05], P = 0.01) were more likely to experience a MACE compared to non-COVID patients. Notably Blacks (aHR = 1.49) and Hispanics (aHR = 1.35) had a higher risk of post COVID-19 MACE. Both hospitalized and non-hospitalized COVID-19 patients were more likely to develop higher cumulative incidence of altered mental status, fatigue, sleep disturbance, dyspnea compared to non-COVID patients (p < 0.05). Conclusions. Patients with pre-existing neurological conditions who contracted COVID-19 were more likely to have worse outcomes compared to controls. Identifying at-risk individuals could enable more diligent follow-up.

show abstract

Long‐term clinical outcomes and healthcare utilization of sickle cell disease patients with COVID‐19: A 2.5‐year follow‐up study

Cited by 3 publications

References 41 publications

Long-term outcomes of patients with Parkinson’s disease 3.5 years post SARS-CoV-2 infection in an inner-city population in the Bronx

Long-term outcomes of patients with Parkinson’s disease 3.5 years post SARS-CoV-2 infection in an inner-city population in the Bronx

SARS-CoV-2 infection increases long-term multiple sclerosis disease activity and all-cause mortality in an underserved inner-city population

Long-Term outcomes of patients with a pre-existing neurological condition after SARS-CoV-2 infection

Contact Info

Product

Resources

About